Characterization of MEDLE-1, a protein in early development of Cryptosporidium parvum

Jilan Fei 1, Haizhen Wu 2, Jiayuan Su 1, Chanchan Jin 1, Na Li 3, Yaqiong Guo 3, Yaoyu Feng 1,3* and Lihua Xiao 3*

Abstract

Background: Cryptosporidium spp. are important diarrhea-causing pathogens in humans and animals. Comparative genomic analysis indicated that Cryptosporidium-specific MEDLE family proteins may contribute to host adaptation of Cryptosporidium spp., and a recent study of one member of this family, CpMEDLE-2 encoded by cgds_4590, has provided evidence supporting this hypothesis. In this study, another member of the protein family, CpMEDLE-1 of Cryptosporidium parvum encoded by cgds_4580, which is distinct from CpMEDLE-2 and has no signature motif MEDLE, was cloned, expressed and characterized to understand its function.

Methods: CpMEDLE-1 was expressed in Escherichia coli and polyclonal antibodies against the recombinant CpMEDLE-1 protein were prepared in rabbits. Quantitative PCR was used to analyze the expression profile of cgds_4580 in C. parvum culture. Immunofluorescence staining was used to locate CpMEDLE-1 expression in life-cycle stages, and in vitro neutralization assay with antibodies was adopted to assess the role of the protein in C. parvum invasion.

Results: The results indicated that cgds_4580 had a peak expression at 2 h of C. parvum culture. CpMEDLE-1 was located in the mid-anterior region of sporozoites, probably within the dense granules. The neutralization efficiency of anti-CpMEDLE-1 antibodies was approximately 40%.

Conclusions: The differences in protein and gene expression profiles between CpMEDLE-1 and CpMEDLE-2 suggest that MEDLE proteins have different subcellular locations, are developmentally regulated, could be potentially involved in the transcriptional regulation of the expression of parasite or host proteins and may exert their functions in different stages of the invasion and development process.

Keywords: Cryptosporidium parvum, MEDLE family, Invasion, Neutralization, Expression

Background

Cryptosporidium spp. are intestinal protozoa that have emerged as an important cause of diarrheal disease in both humans and animals [1]. The severity of Cryptosporidium infection depends on immune status of the host, varying from self-limiting diarrhea in immunocompetent individuals to chronic and life-threatening infection in immunocompromised patients [2]. No effective therapy and vaccines are available against these important pathogens.

Host adaptation is recognized as a general phenomenon in Cryptosporidium spp., with certain species associated with specific hosts [3]. For instance, C. hominis and C. viatorum are largely human-specific, and C. andersoni and C. bovis are mostly cattle-related. A few species such as C. parvum and C. ubiquitum have a broad host range and are generally associated with zoonotic transmission [4]. Even in the latter, host adaptation has been noticed at the subtype family level. For examples, among the three common subtype families in C. parvum, Ila normally infects cattle, IId is commonly...
seen in sheep and goats, while Iic is mostly restricted to humans [5].

Proteins involved in the initial interaction between parasites and hosts are considered candidates involved in host adaptation. A number of candidates are potentially involved in Cryptosporidium attachment and invasion of host cells, such as CP2, P23, gp900, gp15/45 and TRAP-C1 [6]. Most of these molecules are identified as surface or secreted proteins, which are usually encoded by subtelomeric genes or gene families [7]. Many of them are glycosylated and expressed following a unique schedule during intracellular development of the pathogen [8].

Whole genome sequencing of C. parvum has identified several subtelomeric Cryptosporidium-specific gene clusters, encoding putative secreted proteins [9]. The MEDLE family, named after its conserved sequence motif at the C-terminus, is one of them, encoded by two clusters of six genes in the 3' subtelomeric regions of chromosomes 5 and 6. Comparative genomics has identified the occurrence of only one copy of the gene in C. hominis, which differs from C. parvum MEDLE-3 gene at the nucleotide level by 13% [10]. A deletion of one copy of the MEDLE genes was also seen in the IIId subtype family of C. parvum, which has a narrow host range compared with the Ila subtype family [11]. Therefore, it was suggested that MEDLE proteins may be involved in host adaptation of Cryptosporidium spp. Interestingly, Cryptosporidium species divergent from C. parvum and C. hominis, such as C. muris and C. andersoni, do not have any MEDLE genes [12].

In a previous study by our research group [13], we conducted preliminary characterization of CpMEDLE-2, a divergent member of the MEDLE family, and provided evidence to support the hypothesis that MEDLE proteins may play a potential role in the invasion of C. parvum. In order to gain more insight into the biological functions of MEDLE proteins, here we characterized CpMEDLE-1, which is the only one in the protein family of C. parvum that does not have the MEDLE motif at the C-terminus.

**Methods**

**Parasite and cell culture**

*Cryptosporidium parvum* oocysts (IOWA strain) were purchased from Waterborne, Inc. (New Orleans, LA, USA) and stored in antibiotics at 4 °C for less than two months after the harvest. Prior to use, oocysts were treated with 0.5% sodium hypochlorite on ice for 10 min and subsequently washed three times with phosphate-buffered saline (PBS) at 13,200× g for 3 min.

Human ileocecal adenocarcinoma HCT-8 cells (ATCC CCL-244) were obtained from the Chinese Academy of Sciences Shanghai Branch, and cultured in RPMI 1640 medium supplemented with 10% fetal bovine serum (FBS) and 1% penicillin-streptomycin solution (PS) at 37 °C under 5% CO₂. For *in vitro* experiments, HCT-8 cells were seeded into 12-well plates with coverslips and allowed to grow onto coverslips overnight in 10% FBS-supplemented RPMI 1640 medium until reaching ~90% confluence. Afterwards, the culture medium was replaced with fresh 2% FBS-supplemented RPMI 1640 medium. Hypochlorite-treated oocysts were suspended in the culture medium and added into the plates at 5 × 10⁵ oocyst/well. Following a 2 h incubation for excystation and invasion, unexcysted oocysts and free sporozoites were removed by washes in PBS, with fresh 2% FBS-supplemented RPMI 1640 medium added to the culture. The cells were allowed to grow for specified time in different assays.

**Identification of MEDLE homologues and sequence analysis**

The CpMEDLE-1 gene (cgd5_4580) was identified from the C. parvum IOWA genome sequences in the Cryptodb database (http://cryptodb.org) as an intronless gene. Amino acid sequences for other five MEDLE genes in C. parvum and the only MEDLE gene in the C. hominis TU502 genome were also retrieved from Cryptodb and aligned using ClustalX 2.0.11 [14]. Glycosylation sites were predicted using NetOlyc and NetNGlyc (https://www.expasy.org/glycomics). Potential antigenic epitopes were predicted by B Cell Epitopes Prediction Tools (http://tools.immuneepitope.org/main/bcell/). The phylogenetic relationship among MEDLE proteins was assessed by using the maximum likelihood method implemented in MEGA 7.0.26 [15], based on the Poisson distribution model. Bootstrap values were obtained by running 1,000 replicates.

**Cloning, expression and purification of CpMEDLE-1**

The cgd5_4580 gene was amplified from genomic DNA of the C. parvum IOWA isolate with the following primers (the added restriction sites are underlined): forward, 5’-AAA TCC ATG GAA AAT ATA ACC GAT AAT TT-3’; reverse, 5’-AAA TCT CGA GAC TTG TCT CTA CTT TTT TTT T-3’. The template DNA was extracted from C. parvum oocysts by using the Qiagen DNeasy Blood & Tissue Kit (Qiagen, Hilden, Germany). The PCR was performed in a GeneAmp 9700 (Applied Biosystems) with the following cycling conditions: 95 °C for 5 min; 35 cycles of 95 °C for 45 s, 50 °C for 45 s, and 72 °C for 1 min; and 72 °C for 10 min. The amplified product was purified using the SanPre PCR Product Purification Kit (Sangon Biotech, Shanghai, China) and cloned into an Ncol and Xhol double-digested pET28a vector. Recombinant plasmids generated were transformed into competent *Escherichia coli* DH5α cells. The bacterial colonies were screened using T7/T7t universal
primers, with positive colonies being sequenced to confirm their identity and sequence accuracy.

The plasmid harboring the correct insert was transformed into E. coli BL21 (DE3) for protein expression. The BL21 (DE3) cells were cultured in LB medium containing 100 μg/ml kanamycin and grown at 37 °C until the OD600 reached 0.6–1.0, after which 0.5 mM IPTG was added to induce protein expression at 25 °C for 4 h. The expression level and solubility of the target protein were evaluated by using SDS-PAGE and western blot analysis. The band of the expected size was excised from the gel and further analyzed for identity by Matrix-Assisted Laser Desorption/Ionization Time of Flight Mass Spectrometry (MALDI-TOF-MS).

For protein purification, bacteria were inoculated into 2 l of fresh medium and cultured as described above. Afterwards, bacteria were collected by centrifugation, disrupted by sonication on ice and centrifuged again to remove cell debris. The supernatant was filtered through a 0.45 μm cellulose acetate membrane filter (Millipore, Billerica, MA, USA), and loaded onto Ni-NTA beads (Novagen, Madison, WI, USA) at 4 °C and 70 rpm for 2 h. After washing the beads with six volumes of 20 mM imidazole buffer, CpMEDLE-1 was eluted from the beads with elution buffers containing increasing concentrations of imidazole. The purified protein was concentrated by ultrafiltration with an Amicon® Ultra-15 10K Centrifugal Filter Devices (Millipore, Norcross, GA, USA), and examined on a 10% SDS-PAGE gel.

Preparation of anti-CpMEDLE-1 antibodies

Polyclonal antibodies against CpMEDLE-1 were raised in pathogen-free rabbits by GI Biochem Ltd. (Shanghai, China). The primary immunization was conducted on days 1 and 15 using 350 μg of purified CpMEDLE-1 protein emulsified in an equal volume of Freund’s complete adjuvant. Immunized animals received boost immunizations six times every seven days with 150 μg of CpMEDLE-1 protein in Freund’s incomplete adjuvant. Seven days after the final immunization, rabbit sera were collected, and the polyclonal IgG antibodies were purified by using an affinity chromatographic column conjugated with CpMEDLE-1. The titer and specificity of the antibodies were evaluated using an enzyme-linked immunosorbent assay (ELISA) and western blot, respectively.

Western blot analysis of native CpMEDLE-1

To assess the expression of CpMEDLE-1, free sporozoites were prepared from oocysts that were treated with 0.5% sodium hypochlorite as described above and incubated in PBS buffer containing 0.75% taurodeoxycholic acid and 0.25% trypsin at 37 °C for 1 h. The released sporozoites were collected, washed three times by centrifugation with PBS at 13,200× g for 3 min, and re-suspended in PBS containing 1% Triton X-100 and a protease inhibitor cocktail (Merck, Darmstadt, Germany). Proteins (from ~1 × 10⁶ sporozoites/lane) in the lysate were separated on a SDS-PAGE gel. After the transfer of proteins, the nitrocellulose membranes were blocked with 5% nonfat milk-PBST for 2 h, and incubated for 2 h in 5% nonfat milk-PBST supplemented with anti-CpMEDLE-1 antibodies (~0.4 μg/ml), post-immune serum (1:4000) or pre-immune serum (1:4000). Horseradish peroxidase (HRP)-conjugated goat-antirabbit antibodies (Yeasen, Shanghai, China) were employed at 1:5000 as the secondary antibodies in an incubation for another 1 h. The blots were washed three times with PBST after each incubation at room temperature (RT). The reactive protein bands were detected by using an enhanced chemiluminescent reagent (Thermo Fisher, Rockford, IL, USA).

Assessment of cross-reactivity of anti-CpMEDLE-1 antibodies to other MEDLE proteins

To determine whether anti-CpMEDLE-1 antibodies cross-react with other MEDLE proteins, CpMEDLE-2 and two other MEDLE members under study in our research group, CpMEDLE-3 (encoded by cgd5_4600) and CpMEDLE-5 (encoded by cgd6_5480), were employed as antigens in incubations with anti-CpMEDLE-1 antibodies. The concentrations of individual proteins were determined by using a BCA Protein Quantification Kit (Yeasen, Shanghai, China). ELISA was performed to assess the dose response of anti-CpMEDLE-1 antibodies. For this, proteins were coated onto the ELISA plates and anti-CpMEDLE-1 antibodies (1.55 mg/ml) were added at dilutions of 1:1000, 1:2000, 1:4000, 1:8000 and 1:16,000. Pre-immune serum was employed as the negative control. HRP-conjugated goat-anti-rabbit secondary antibodies were used for detection of reactivity to the coated antigens by the anti-CpMEDLE-1 antibodies, with absorbance being measured at 450 nm. The relative absorbance values of samples to negative control greater than 2.1 were considered positive. The cross-reactivity of anti-CpMEDLE-1 antibodies to other MEDLE proteins was also assessed by using western blot analysis of MEDLE proteins (1 μg/lane) as described above.

Quantitation of cgd5_4580 gene expression

The relative expression level of the cgd5_4580 gene in intra-cellular parasites in HCT-8 cultures at 0–72 h was evaluated by qPCR. The expression of C. parvum 18Sr rRNA (Cp18S rRNA) gene was used for data normalization. Total RNA at each culture point was isolated from C. parvum-infected HCT-8 cells using an RNeasy Mini Kit (Qiagen), and quantitated and assessed for purity using NanoDrop 2000. Each of the qPCR reaction contained 0.1 mM primers, 1 μl of cDNA synthesized from 2 μg of RNA using a GoScript™
Reverse Transcription System (Promega, Beijin, China), and 10 μl of SYBR Green PCR Mix (TOYOBO, Osaka, Japan) in a 20 μl volume. The reaction was run on a LightCycler® 480 (Roche, Basel, Switzerland), with 45 cycles of 95 °C for 30 s, 58 °C for 30 s, and 72 °C for 30 s. The following primers specific to cgds5_4580 were used in qPCR: 5’-GGT TCG AGT AGA GGT GGA GGT-3’ and 5’-AGA AGG GAC CAT AGC GAT CA-3’ (amplicon size = 216 bp), together with published Cpg18S rRNA qPCR primers 5’-CTC CAC CAA CTA AGA ACG GCC-3’ and 5’-TAG AGA CCG AGG ACG CTC-3’ (amplicon size = 256 bp) [16]. The cultivation assays were carried out in triplicate and qPCR analysis of each RNA extraction was performed in duplicate. Relative levels of gene expression were calculated by using the 2^{-\Delta\Delta CT} method [17], where differences between threshold cycle (CT) values were first determined by computing the \( \Delta CT \) between target gene transcripts (CT [CpMEDLE-1]) and Cpg18S rRNA (CT [Cpg18S]) as \( \Delta CT = CT_{[CpMEDLE-1]} - CT_{[Cpg18S]} \). The \( \Delta CT \) values of each time points were then normalized by subtracting the minimum \( \Delta CT \) value (\( \Delta CT_{[min]} \)) among them as \( \Delta \Delta CT = \Delta CT - \Delta CT_{[min]} \).

**Immunofluorescence assay (IFA)**
Free sporozoites were harvested and re-suspended in a drop of PBS on a microscope slide. Intracellular stages of C. parvum were obtained by infecting HCT-8 cells grown on coverslips for 24 and 48 h. The slide and coverslips were fixed at RT in methanol for 15 min. After three washes in PBS, the fixed cells were permeabilized with 0.5% Triton X-100 in PBS for 15 min, washed three times with PBS, blocked with 5% BSA in PBS (BSA-PBS) at RT for 1 h, incubated with anti-CpMEDLE-1 antibodies (~0.4 μg/ml) in 5% BSA-PBS for 1 h. After three washes in PBS, the cells were incubated with Alexa Fluor® 594-conjugated Goat Anti-rabbit IgG (Cell Signaling Technology, MA, USA) in BSA-PBS at 1:400 for 1 h. After three washes with PBS, the cells were counterstained with the nuclear stain 4’,6-diamidino-2-phenylindole (DAPI, Roche, Basel, Switzerland). After another three washes with PBS, the slide or coverslips were mounted with No-Fade Mounting Medium (Booster, Wuhan, China) and examined by differential interference contrast (DIC) and fluorescence microscopy using a BX53 immunofluorescence microscope (Olympus, Tokyo, Japan).

**Invasion neutralization assay**
Neutralization assays were performed to assess the potential role of CpMEDLE-1 protein in C. parvum invasion. Hypochlorite-treated oocysts were pre-incubated at 37 °C in medium containing increasing dilutions of post-immune serum for 15 min, with pre-immune serum or medium alone as controls. They were added onto HCT-8 cells grown to ~90% confluence in 12-well plates as described before. The dilutions of serum used included 1:200, 1:500 and 1:1000. After 2 h incubation, the HCT-8 cells were washed three times and incubated in fresh culture medium for additional 24 h. To assess the infection rate of HCT-8 cells, the culture on coverslips was stained with Cy3-labeled Sporo-Glo™ antibodies (Waterborne, New Orleans, LA, USA) and examined under the immunofluorescence microscope. Images were captured randomly from 50 microscope fields per coverslip under 200×, and the total number of parasites in the fields was quantified by using Image J 1.4.3.67 (https://imagej.nih.gov/ij/).

All experiments were performed in triplicate and the data generated were compared using a Student’s t-test. The neutralization efficiency of anti-CpMEDLE-1 antibodies at different dilutions was calculated based on differences in parasite load between antibody-treated groups and their corresponding controls.

**Results**

**Sequence characteristics of CpMEDLE-1**
CpMEDLE-1 is a putative secretory protein encoded by the cgds5_4580 gene in the 3’ subtelomeric region of chromosomes 5 of C. parvum. The sequence contains 230 amino acids with a predicted signal peptide at amino acids 1–23 and a transmembrane domain at 7–26. It has 14 predicted O-linked glycosylation sites involving one threonine and 13 serine residues, as well as two predicted N-linked glycosylation sites at amino acids 25 and 143 (Fig. 1a). Among MEDLE proteins, by in silico analysis, there is an ATP-dependent RNA helicase domain in CpMEDLE-1 and ChMEDLE-1, a serine/threonine protein kinase domain in CpMEDLE-2, and a histone chaperone domain in CpMEDLE-4 and CpMEDLE-6. In addition, CpMEDLE-1 possesses six low complexity regions (LCRs) along the sequence, which are also present in other MEDLE proteins (Fig. 1b). Multiple sequence alignment of MEDLE family proteins of C. parvum and C. hominis has revealed a high sequence identity among them. However, CpMEDLE-1 appears to be a truncated member of the family and does not have the motif “MEDLE” at the C-terminus of the protein. CpMEDLE-2 is the most divergent member of the family, with only 36% sequence identity to CpMEDLE-1, compared with the 67% and 56% identities by CpMEDLE-3 and CpMEDLE-5, respectively. In B cell epitope prediction, the conserved regions of MEDLE proteins have overlapping epitopes, suggesting that polyclonal antibodies against CpMEDLE-1 could have immunological cross-reactivity with other MEDLE proteins. The phylogenetic tree inferred from C. parvum and C. hominis MEDLE proteins indicated that
CpMEDLE-1 is most related to CpMEDLE-3, followed by ChMEDLE-1, CpMEDLE-4, CpMEDLE-5 and CpMEDLE-6 (Fig. 1c).

Expression of recombinant CpMEDLE-1
We cloned, expressed and purified recombinant CpMEDLE-1 protein with a His-tag (Fig. 2a, b). In western blot analysis, CpMEDLE-1 migrated with a molecular mass consistent with the predicted size of ~23 KDa. However, there was a consistent presence of another larger band of ~37 KDa. To confirm their CpMEDLE-1 identity, both bands were analyzed by using MALDI-TOF-MS, yielding peptide sequences of CpMEDLE-1 (Accession No. XM_625306; data not...
shown). Thus, the larger one could be a dimer of the CpMEDLE-1 protein. No obvious differences in the dimer formation were observed when treating the proteins with either dithiothreitol or ultracentrifugation.

For the characterization of CpMEDLE-1, we performed a series of western blots with the anti-CpMEDLE-1 antibody preparation and post-immune serum, with the pre-immune serum as control (Fig. 2c). The purified recombinant CpMEDLE-1 was recognized as expected, with two expected bands of ~23 KDa and ~37 KDa, and two other smaller bands that were more likely degraded products of CpMEDLE-1. In contrast, a total protein extract from sporozoites produced three bands of ~50 KDa, ~36 KDa and ~32 KDa, suggesting the possibility of antibodies reacting with multiple native MEDLE proteins in C. parvum. Because all three bands were larger than the predicted sizes of MEDLE proteins, post-translational O-linked and N-linked glycosylation could be responsible for the discrepancy in predicted and observed sizes of MEDLE proteins. As expected, the pre-immune serum had no reactivity with either purified CpMEDLE-1 or native protein.

Cross-reactivity of CpMEDLE-1 antibodies with other MEDLE proteins

The cross-reactivity of anti-CpMEDLE-1 antibodies (1.55 mg/ml) against other MEDLE proteins was validated by western blot and ELISA (Fig. 2d). The result of western blot analysis showed some cross-reactivity of anti-CpMEDLE-1 antibodies to CpMEDLE-2, CpMEDLE-3 and CpMEDLE-5, with relatively weak bands in blots of other MEDLE proteins compared with obvious recognition of CpMEDLE-1. The cross-reactivity of the antibodies was further evaluated by ELISA analysis using different dilutions of anti-CpMEDLE-1 antibodies. In ELISA analysis, equal amounts of these four MEDLE proteins coated on plates were incubated with different dilutions of anti-CpMEDLE-1 antibodies, with pre-immune serum as the negative control. Any OD 450 ratio greater than 2.1 was regarded as positive immunoreactivity.

Differential expression of CpMEDLE-1 in C. parvum

To assess the expression profile of the CpMEDLE-1 gene during intracellular development, qPCR was performed...
over a 72 h time course in *C. parvum*-infected HCT-8 cells. When normalized with data from the *Cp18S* rRNA gene, the expression of *CpMEDLE-1* decreased gradually during the culture period (Fig. 3a). The highest expression level was detected at 2 h post-infection.

In examination of *CpMEDLE-1* expression by immunofluorescence microscopy of developmental stages, the anti-*CpMEDLE-1* antibodies (~0.4 μg/ml) reacted with the mid-anterior region of sporozoites (Fig. 3b, top panel). At 24 h of the cell culture, type I meronts had the highest of reactivity to the antibodies in part of the merozoites (Fig. 3b, middle panel). At 48 h, the reactivity of the antibodies to mature type I meronts appeared to be still restricted to part of the merozoites (Fig. 3b, bottom panel).

**Inhibition of *C. parvum* invasion by anti-*CpMEDLE-1* antibodies**

Neutralization assays were carried out to assess the effect of anti-*CpMEDLE-1* antibodies on *C. parvum* invasion of HCT-8 cells. In comparison with the control culture, the mean parasite loads had a modest but significant reduction when the cell culture was inoculated with sporozoites treated with antisera from *CpMEDLE-1* immunized rabbits (Fig. 3c). The inhibitory effect was 21.9% (26.8 ± 3.5 and 20.9 ± 4.1 per 200× field for pre- and post-immune serum, respectively; *t* = 8.154, *P* = 0.015) at the 1:1000 dilution, 39.0% (25.5 ± 4.2 and 15.6 ± 1.2 per 200× field for pre- and post-immune serum, respectively; *t* = 4.983, *P* = 0.038) at the 1:500 dilution, and 37.0% (24.3 ± 5.2 and 15.3 ± 3.0 per 200× field for pre- and post-immune serum, respectively; *t* = 4.678, *P* = 0.043) at the 1:200 dilution.

**Discussion**

Our results suggested that *CpMEDLE-1* protein could play a role in invasion or early development of *C. parvum* based on the following evidence: (i) the expression of the *CpMEDLE-1* gene peaked at 2 h post-infection, just after the entry of sporozoites into culture cells [18]; (ii) polyclonal antibodies against *CpMEDLE-1* resulted in a reduction in parasite infection at approximately 40%. The reduction is moderate since apicomplexan are known to use various strategies for invasion [19]; (iii) *CpMEDLE-1* was identified to locate in the mid-anterior region of sporozoites. During sporozoite invasion, the molecules mediating attachment tend to locate apically, whereas those mediating invasion can locate elsewhere on the surface of or within sporozoites [20].
Despite CpMEDLE-1 was not located apically as expected, it could still be involved in early growth and development of *C. parvum*.

Although CpMEDLE-1 is considered to participate in invasion or early development of the pathogen, the subcellular location of CpMEDLE-1 remains unclear. Our data localized CpMEDLE-1 to the mid-anterior region of sporozoites. Even though we were unable to position it precisely to any organelle due to the technique used, the mid-anterior location of the protein is in agreement with the location of dense granules [21]. The expression of CpMEDLE-1 in merozoites appears to be similar, as only a small part of the merozoites reacted with anti-CpMEDLE-1 antibodies. Further studies using immunofluorescence electron microscopy are needed for precise subcellular localization of CpMEDLE-1.

In comparison with CpMEDLE-2, CpMEDLE-1 has shown unique sequence characteristics and a very different expression profile [13]. In direct sequence comparison and phylogenetic analysis, CpMEDLE-2 is divergent from CpMEDLE-1 and other MEDLE proteins. This is also supported by comparisons of protein domains, which have shown the presence of ATP-dependent RNA helicase or histone chaperone domains in CpMEDLE-1 and some other MEDLE proteins, compared with the serine/threonine protein kinase domain in CpMEDLE-2. While the expression of CpMEDLE-1 in sporozoites appears to be restricted to dense granules, the expression of CpMEDLE-2 is diffused throughout the sporozoites. The expression of genes encoding the two proteins also appears to be significantly different in vitro culture, with peak expression at 2 h and 48 h, respectively. Thus, data obtained thus far suggest that MEDLE proteins are developmentally regulated and may express their functions in different developmental stages.

The function of MEDLE proteins is unclear, but here we offer a hypothesis on their role in immune evasion by the *C. parvum*. As predicted in silico, MEDLE proteins are characterized with the presence of domains for ATP-dependent RNA helicase, histone chaperone, and serine/threonine protein kinase. The former two are known to be involved in transcriptional regulations while the latter is well known to target immunity-related GTPases (IRGs) for host immunity evasion in *Toxoplasma gondii* [22, 23]. Thus, in addition to regulating parasite gene transcription during parasite growth and development, the secretion of these proteins into host cells during invasion could modulate host gene expression and serve as an immune evasion mechanism. Indeed, recent studies have demonstrated the delivery of several *C. parvum* RNA transcripts into host cells during the infection, modulating the transcription of host genes involved in immune defense [24]. It was further demonstrated that histone modification-mediated epigenetic mechanisms may contribute to this nuclear delivery and transcriptional suppression [25].

The potential role of MEDLE proteins in immune evasion is also supported by the presence of LCRs. LCRs are prevalent in *Cryptosporidium* spp. and other apicomplexans, characterized by low diversity in residues, such as homopolymers, short tandem repeats or aperiodic mosaics [26, 27]. Previous studies had shown that these regions might undergo rapid evolution due to their high compositional plasticity [28], or play a role in immune invasion because of the ability to swiftly changing immunodominant epitopes on antigens [29].

**Conclusions**

We have expressed a *Cryptosporidium*-specific secreted protein CpMEDLE-1, and observed significant differences in gene and protein expressions in *C. parvum* compared with the previously studied CpMEDLE-2. Our results indicate that CpMEDLE-1 might be a dense granule protein and potentially could be involved in the transcriptional regulation of the expression of parasite or host proteins. These conclusions should be substantiated with data generated using more advanced molecular biological tools, including those generated using gene knockout approaches such as the CRISPR/Cas9 system.

**Abbreviations**

BSA: Bovine serum albumin; DAPI: 4′, 6-diamidino-2-phenylindole; ELISA: Enzyme-linked immunosorbent assay; FBS: Fetal bovine serum; HRP: Horseradish peroxidase; LCRs: Low complexity regions; MALDI-TOF-MS: Matrix-Assisted Laser Desorption/Ionization Time of Flight Mass Spectrometry; PBS: Phosphate-buffered saline; RT: Room temperature; SDS-PAGE: Sodium dodecyl sulfate polyacrylamide gel electrophoresis

**Funding**

This research was supported by the National Nature Science Foundation of China (31630078 and 31425025).

**Availability of data and materials**

The data supporting the conclusions of this article are included within the article. The MEDLE protein sequences used in the study were retrieved from *Cryptospora*db under NCBI accession numbers XP_625306-XP_625309, XP_625312, XP_666030, and XP_666030.

**Authors’ contributions**

JF conceived and designed the experiments. JF, JS and CJ performed the experiments. JF, YF, HW, GQ, NL and LX analyzed the data. JF, YF and LX wrote the paper. All authors read and approved the final manuscript.

**Ethics approval and consent to participate**

This study was approved by the Ethics Committee of the East China University of Science and Technology.

**Competing interests**

The authors declare that they have no competing interests.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details
1State Key Laboratory of Bioreactor Engineering, School of Resources and Environmental Engineering, East China University of Science and Technology, Shanghai 200237, China. 2School of Biotechnology, East China University of Science and Technology, Shanghai 200237, China. 3Key Laboratory of Zoonosis of Ministry of Agriculture, College of Veterinary Medicine, South China Agricultural University, Guangzhou 510642, China.

Received: 7 March 2018 Accepted: 7 May 2018
Published online: 23 May 2018

References
1. Checkley W, White AC, Jaganath D, Arrowood MJ, Chalmers RM, Chen XM, et al. A review of the global burden, novel diagnostics, therapeutics, and vaccine targets for Cryptosporidium. Lancet Infect Dis. 2015;15:85–94.
2. Chalmers RM, Davies AP. Minireview: clinical cryptosporidiosis. Exp Parasitol. 2010;124:138–46.
3. Xiao LH, Sulaiman IM, Ryan UM, Zhou L, Atwill ER, Tischler ML, et al. Comparative genomic analysis of the IId subtype family of Cryptosporidium parvum. Science. 2004;304(5669):441–4.
4. Ryan U, Fayer R, Xiao LH. Cryptosporidium species in humans and animals: current understanding and research needs. Parasitology. 2014;141:667–85.
5. Xiao LH. Molecular epidemiology of cryptosporidiosis: an update. Exp Parasitol. 2010;124:80–9.
6. Lendner M, Daugiches A. Cryptosporidium infections: molecular advances. Parasitology. 2014;141:1511–32.
7. Bouzid M, Hunter PR, Chalmers RM, Tyler KM. Cryptosporidium parvum: implications for taxonomy and public health. Int J Parasitol. 2002;32:1773–85.
8. Ryan U, Fayer R, Xiao LH. Cryptosporidium species in humans and animals: current understanding and research needs. Parasitology. 2014;141:667–85.
9. Xiao LH. Molecular epidemiology of cryptosporidiosis: an update. Exp Parasitol. 2010;124:80–9.
10. Guo YQ, Tang K, Rowe LA, Li N, Roellig DM, Knipe KD, et al. Host adaptation and host-parasite co-evolution in Cryptosporidium: implications for taxonomy and public health. Int J Parasitol. 2002;32:1773–85.
11. Feng YY, Li N, Roellig DM, Kelley A, Liu GY, Amer S, et al. Comparative genomic analysis reveals occurrence of genetic recombination in virulent Cryptosporidium hominis subtypes and telomeric gene duplications in Cryptosporidium parvum. BMC Genomics. 2015;16:320.
12. Jakob V, Petry F. Differential expression of Cryptosporidium parvum genes encoding sporozoite surface antigens in infected HCT-8 host cells. Microbes Infect. 2006;8:2186–94.
13. Abrahamsen MS, Templeton TJ, Enomoto S, Abrahante JE, Zhu G, Lancto CA, et al. Complete genome sequence of the apicomplexan, Cryptosporidium parvum. Science. 2004;304(5669):441–5.
14. Guo YQ, Tang K, Rowe LA, Li N, Roellig DM, Knipe KD, et al. Comparative genomic analysis reveals occurrence of genetic recombination in virulent Cryptosporidium hominis subtypes and telomeric gene duplications in Cryptosporidium parvum. BMC Genomics. 2015;16:320.
15. Peng YY, Li N, Roellig DM, Kelley A, Liu GY, Amer S, et al. Comparative genomic analysis of the IId subtype family of Cryptosporidium parvum. Int J Parasitol. 2017;47:281–90.
16. Liu SY, Roellig DM, Guo YQ, Li N, Frace MA, Tang K, et al. Evolution of mitosome metabolism and invasion-related proteins in Cryptosporidium. BMC Genomics. 2016;17:1006.
17. Li B, Wu HZ, Li N, Su JY, Jia RL, Jiang JL, et al. Preliminary characterization of MEDLE-2, a protein potentially involved in the invasion of Cryptosporidium parvum. Front Microbiol. 2017;8:1647.
18. Larkin MA, Blackshields G, Brown NP, Chenna R, McGettigan PA, McWilliam H, et al. Clustal W and Clustal X version 2.0. Bioinformatics. 2007;23:2947–8.
19. Kumar S, Stecher G, Tamura K. MEGA7: Molecular Evolutionary Genetics Analysis version 7.0 for bigger datasets. Molecular Biology and Evolution. 2017;33:1780–4.
20. Mauzy MJ, Enomoto S, Lancto CA, Abrahamsen MS, Rutherford MS. The Cryptosporidium parvum transcriptome during in vitro development. PLoS Pathog. 2012;8:e1002715.
21. Livan KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 2001;25:402–8.
22. Borowski H, Thompson RC, Armstrong T, Clode PL. Morphological characterization of Cryptosporidium parvum life-cycle stages in an in vitro model system. Parasitology. 2010;137:13–26.
23. Sibley LD. Intracellular parasite invasion strategies. Science. 2004;304(5668):248–53.
24. Borowski H, Clode PL, Thompson RC. Active invasion and/or encapsulation? A reappraisal of host-cell parasitism by Cryptosporidium. Trends Parasitol. 2008;24:509–16.

Ready to submit your research? Choose BMC and benefit from:
• fast, convenient online submission
• thorough peer review by experienced researchers in your field
• rapid publication on acceptance
• support for research data, including large and complex data types
• gold Open Access which fosters wider collaboration and increased citations
• maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.
Learn more biomedcentral.com/submissions